Delivery Order SPE2DB22D9316-SPE2DB24FYP59

Award Date 6/28/24
Potential Completion Date 7/22/24
Potential Value $5.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $51,095.52 contract is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. This delivery order is issued under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which enables the agency to procure a wide range...
The Defense Logistics Agency (DLA) awarded a $51,581.80 firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of TYSABRI 300 MG/15 ML VIAL 15ML. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, SPE2DB24FPQG7, valued at up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical products to support military medical facilities. DMS Pharmaceutical...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a $41,265.44 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Tysabri 300 mg/15 ml vials over a period ending on May 15, 2024. This delivery order was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,262.76 firm fixed-price delivery order is for the procurement of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery...
This is a delivery order valued at $10,316.36 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of Tysabri 300 mg/15 ml vials with a completion date of June 11, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to DMS Pharmaceutical Group by the DLA under the SPE2DB program, valued at up to $499,999,999 through...
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $5,158.18 contract is for the delivery of Tysabri, a 300 mg/15 mL injectable biologic medication, with a performance period through September 17, 2024. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product, with a ceiling value of $5,262.76 and a period of performance through April 22, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,547.76 contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price contract is for the delivery of the pharmaceutical product Tysabri 300 mg/15 ml vial to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers. The award is not associated with a specific set-aside designation, allowing DMS...
  • SPE2DB22D9316
    Indefinite Delivery Contract
  • SPE2DB22D9316-SPE2DB24FYP59
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,158.18 order is for TYSABRI 300 MG/15 ML VIAL 15ML, a biologic medication. The order has a completion date of July 22, 2024.

This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This single-award IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group also holds separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to Department of Defense sites.

The contract award does not utilize any set-aside designations. DMS Pharmaceutical Group's status as a woman-owned small business has enabled it to secure these federal contract awards from the DLA to provide pharmaceutical products and services to the Department of Defense.

Generated 9/27/24, 9:41 AM